Worldwide Overview of the Current Status of Lung Cancer Diagnosis and Treatment
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Worldwide Overview of the Current Status of Lung Cancer Diagnosis and Treatment
Authors
Keywords
-
Journal
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
Volume 136, Issue 12, Pages 1478-1481
Publisher
Archives of Pathology and Laboratory Medicine
Online
2012-11-30
DOI
10.5858/arpa.2012-0295-sa
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2012
- (2012) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung
- (2012) Ji-Youn Han et al. JOURNAL OF CLINICAL ONCOLOGY
- The Novel Histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification System of Lung Adenocarcinoma Is a Stage-Independent Predictor of Survival
- (2012) Arne Warth et al. JOURNAL OF CLINICAL ONCOLOGY
- A new generation of EGFR tyrosine-kinase inhibitors in NSCLC
- (2012) Fred R Hirsch et al. LANCET ONCOLOGY
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- Oral Iloprost Improves Endobronchial Dysplasia in Former Smokers
- (2011) R. L. Keith et al. Cancer Prevention Research
- Screening by Chest Radiograph and Lung Cancer Mortality
- (2011) Martin M. Oken et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
- (2011) William D. Travis et al. Journal of Thoracic Oncology
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- (2011) Caicun Zhou et al. LANCET ONCOLOGY
- Selenium and Lung Cancer: A Systematic Review and Meta Analysis
- (2011) Heidi Fritz et al. PLoS One
- Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
- (2010) M. Reck et al. ANNALS OF ONCOLOGY
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- (2010) Eunice L. Kwak et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
- (2009) Tetsuya Mitsudomi et al. LANCET ONCOLOGY
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prostacyclin Prevents Murine Lung Cancer Independent of the Membrane Receptor by Activation of Peroxisomal Proliferator-Activated Receptor
- (2008) R. Nemenoff et al. Cancer Prevention Research
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
- (2008) Giorgio Vittorio Scagliotti et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now